example 13 [WO2009109743]   Click here for help

GtoPdb Ligand ID: 9077

Compound class: Synthetic organic
Comment: This is one of the fatty acid amide hydrolase 1 (FAAH) inhibitor compounds claimed in patent WO2009109743 [2]. FAAH inhibitors are being investigated for their potential analgesic action.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 80.24
Molecular weight 347.14
XLogP 2.67
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(N1CC(C1)Oc1ccc(cn1)c1ccccc1)Nc1cccnn1
Isomeric SMILES O=C(N1CC(C1)Oc1ccc(cn1)c1ccccc1)Nc1cccnn1
InChI InChI=1S/C19H17N5O2/c25-19(22-17-7-4-10-21-23-17)24-12-16(13-24)26-18-9-8-15(11-20-18)14-5-2-1-3-6-14/h1-11,16H,12-13H2,(H,22,23,25)
InChI Key VSQUREFTKYDATG-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
One of the compounds claimed in Vernalis' patent WO2009109743 [2] is likely be V158866, an FAAH inhibitor evaluated in clinical trials. Phase 1 V158866 results are published in [1]. A Phase 2 trial in patients with central neuropathic pain following spinal cord injury has been completed (see NCT01748695), but due to a lack of efficacy, Vernalis has suspended further development of V158866.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
FAAH breaks down fatty acid amides such as anandamide (N-arachidonoylethanolamine, AEA), N-oleoylethanolamide and oleamide. Inhibitors of FAAH lead to elevated anandamide levels and modulate activation of the cannabinoid receptor pathway. This mechanism has been proposed as a novel way to treat pain.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01748695 A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury Phase 2 Interventional Brigham and Women's Hospital